Targeting brain cells to improve treatment for Alzheimer's disease
Official title: Targeting brain myeloid cells with siRNA-lipid conjugates for treatment of Alzheimer's disease
Funded at Vanderbilt University · NIH-11073756 · Data updated 2026-11-12
This study is testing a new way to deliver a special treatment to brain cells that could help reduce the harmful effects of Alzheimer's disease, making it easier for the body to clear out a substance that contributes to the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | December 1, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $787,103 |
| NIH project number | 1R01AG092015-01 |
| Project ID | NIH-11073756 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk for developing it due to genetic factors.
✕Less likely to help
Patients with other forms of dementia or neurological disorders unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research focuses on developing a new method to deliver small interfering RNA (siRNA) to brain myeloid cells, which play a crucial role in Alzheimer's disease. By using a novel lipid conjugate, the study aims to enhance the delivery and effectiveness of siRNA that can reduce the expression of genes associated with Alzheimer's, such as CD33. The approach involves administering the siRNA into the cerebrospinal fluid, where it can be transported effectively to target cells throughout the brain. This innovative method seeks to improve the clearance of amyloid beta, a key factor in Alzheimer's pathology.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease by improving the clearance of harmful proteins in the brain.
How similar studies have gone: Previous research has shown promise in using similar oligonucleotide approaches for targeting brain cells, indicating potential for success in this novel application.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Lippmann, Ethan — Vanderbilt University
- Study coordinator: Lippmann, Ethan
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.